他汀类药物与乳腺癌预后的关系
The Relationship between Statins and the Prognosis of Breast Cancer
DOI: 10.12677/ACM.2021.118532, PDF,   
作者: 路 娜：青海大学，青海 西宁；王淼舟*：青海大学附属医院乳腺疾病诊疗中心，青海 西宁
关键词: 乳腺癌；他汀类药物；芳香化酶抑制剂；Breast Cancer； Statins； Aromatase Inhibitors
摘要: 他汀类药物是临床上主要应用于针对心血管疾病的降脂药物，近年来，越来越多的研究证实了他汀类降脂药的抗肿瘤作用。在乳腺癌领域，他汀类药物被认为可以降低乳腺癌患者复发风险，降低乳腺癌的死亡率。对于乳腺癌辅助内分泌治疗的患者来说，口服芳香化酶抑制剂导致部分患者血脂异常，从而增加心血管疾病的发生。他汀类药物不仅在降脂上作用显著，其改善乳腺癌患者预后作用意义重大。
Abstract: Statins are mainly used clinically as lipid-lowering drugs for cardiovascular diseases. In recent years, more and more studies have confirmed the anti-tumor effects of statins. In the field of breast cancer, statins are believed to reduce the risk of recurrence of breast cancer patients and reduce the mortality rate of breast cancer. For patients undergoing adjuvant endocrine therapy for breast cancer, oral aromatase inhibitors can cause dyslipidemia in some patients, thereby increasing the incidence of cardiovascular disease. Statins not only have a significant effect on lowering lipids, but also have great significance in improving the prognosis of breast cancer patients.
文章引用：路娜, 王淼舟. 他汀类药物与乳腺癌预后的关系[J]. 临床医学进展, 2021, 11(8): 3632-3637. https://doi.org/10.12677/ACM.2021.118532

参考文献

[1] Beckwitt, C.H., Clark, A.M., Ma, B., Whaley, D., Oltvai, Z.N. and Wells, A. (2018) Statins Attenuate Outgrowth of Breast Cancer Metastases. British Journal of Cancer, 119, 1094-1105. [Google Scholar] [CrossRef] [PubMed]
[2] Yousef, A. and Jad, A. (2017) Male Breast Cancer: Epidemiology and Risk Factors. Seminars in Oncology, 44, 267-272.
[3] 王芹, 李德俊, 吴玉萍. 内分泌治疗对绝经后乳腺癌患者血脂和骨骼健康的影响[J]. 中国当代医药, 2018, 25(29): 46-48.
[4] 于世英. 长期服用芳香化酶抑制剂的不良反应处理[C]//中国癌症基金会、中国抗癌协会肿瘤临床化疗专业委员会、中华医学会肿瘤学分会、全国肿瘤防治研究办公室、中国医学科学院肿瘤医院. 第三届中国肿瘤内科大会教育集暨论文集. 2009: 216-218.
[5] Hershman, D.L., Till, C., Shen, S., et al. (2018) Association of Cardiovascular Risk Factors with Cardiac Events and Survival Outcomes among Patients with Breast Cancer Enrolled in SWOG Clinical Trials. Journal of Clinical Oncology, 36, 2710-2717. [Google Scholar] [CrossRef] 
[6] Mauriac, L., Keshaviah, A., Debled, M., Mouridsen, H., Forbes, J.F., Thürlimann, B., Paridaens, R., Monnier, A., Láng, I., Wardley, A., Nogaret, J.M., Gelber, R.D., Castiglione-Gertsch, M., Price, K.N., Coates, A.S., Smith, I., Viale, G., Rabaglio, M., Zabaznyi, N., Goldhirsch, A., BIG 1-98 Collaborative Group and International Breast Cancer Study Group (2007) Predictors of Early Relapse in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer in the BIG 1-98 Trial. Annals of Oncology, 18, 859-867. [Google Scholar] [CrossRef] [PubMed]
[7] Smith, I., Yardley, D., Burris, H., et al. (2017) Comparative Efficacy and Safety of Adjuvant Letrozole versus Anastrozole in Postmenopausal Patients with Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara versus Anastrozole Clinical Evaluation (FACE) Trial. Journal of Clinical Oncology, 35, 1041-1048.
[8] Wang, X., Zhu, A.J., Wang, J.Y., et al. (2020) Steroidal Aromatase Inhibitors Have a More Favorable Effect on Lipid Profiles than Nonsteroidal Aromatase Inhibitors in Postmenopausal Women with Early Breast Cancer: A Prospective Cohort Study. Therapeutic Advances in Medical Oncology, 12. [Google Scholar] [CrossRef] [PubMed]
[9] Endo, A. (2008) A Gift from Nature: The Birth of the Statins. Nature Medicine, 14, 1050-1052. [Google Scholar] [CrossRef] [PubMed]
[10] Ahern, T.P., Lash, T.L., Damkier, P., Christiansen, P.M. and Cronin-Fenton, D.P. (2014) Statins and Breast Cancer Prognosis: Evidence and Opportunities. The Lancet Oncology, 15, e461-e468. [Google Scholar] [CrossRef] 
[11] Bersot, T. (2011) Drug Therapy for Hypercholesterolemia and Dyslipidemia. In: Brunton, L.L., Chabner, B.A. and Knollman, B.C., Eds., Goodman & Gilman’s the Pharmacological Basis of Therapeutics, 12th Edition, McGraw-Hill, New York, 933-966.
[12] Lamond, A.I. (2002) Review of: Molecular Biology of the Cell, 4th Edition. Nature, 417, 383. [Google Scholar] [CrossRef] 
[13] Rosch, P.J. and McCully, K. (2013) Statin Use and Reduced Cancer-Related Mortality. The New England Journal of Medicine, 368, 576. [Google Scholar] [CrossRef] 
[14] Niemi, M., Pasanen, M.K. and Neuvonen, P.J. (2011) Organic Anion Transporting Polypeptide 1B1: A Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake. Pharmacological Reviews, 63, 157-181. [Google Scholar] [CrossRef] [PubMed]
[15] 孙忠实. 关于他汀类药若干争议的思考——从临床药理学角度诠释[J]. 中国医院用药评价与分析, 2014, 14(2): 97-99.
[16] 闫冰. 辛伐他汀联合紫杉醇靶向作用Hippo信号通路对乳腺癌干细胞的影响[D]: [硕士学位论文]. 大连: 大连医科大学, 2017.
[17] Crescencio, M.E., Rodríguez, E., Páez, A., et al. (2009) Statins Inhibit the Proliferation and Induce Cell Death of Human Papilloma Virus Positive and Negative Cervical Cancer Cells. International Journal of Biomedical Science, 5, 411-420.
[18] Beckwitt, C.H., Shiraha, K. and Wells, A. (2018) Lipophilic Statins Limit Cancer Cell Growth and Survival, via Involvement of Akt Signaling. PLoS ONE, 13, e0197422. [Google Scholar] [CrossRef] [PubMed]
[19] Ghosh-Choudhury, N., Mandal, C.C., Ghosh-Choudhury, N. and Ghosh Choudhury, G. (2010) Simvastatin Induces Derepression of PTEN Expression via NFkappaB to Inhibit Breast Cancer Cell Growth. Cell Signal, 22, 749-758. [Google Scholar] [CrossRef] [PubMed]
[20] Gopalan, A., Yu, W., Sanders, B.G., et al. (2013) Simvastatin Inhibition of Mevalonate Pathway Induces Apoptosis in Human Breast Cancer Cells via Activation of jnk/chop/dr5 Signaling Pathway. Cancer Letters, 329, 9-16. [Google Scholar] [CrossRef] [PubMed]
[21] Benn, M., Tybjærg-Hansen, A., Stender, S., Frikke-Schmidt, R. and Nordestgaard, B.G. (2011) Low-Density Lipoprotein Cholesterol and the Risk of Cancer: A Mendelian Randomization Study. Journal of the National Cancer Institute, 103, 508-519. [Google Scholar] [CrossRef] [PubMed]
[22] Thurnher, M., Gruenbacher, G. and Nussbaumer, O. (2013) Regulation of Mevalonate Metabolism in Cancer and Immune Cells. Biochimica et Biophysica Acta, 1831, 1009-1015. [Google Scholar] [CrossRef] [PubMed]
[23] Clendening, J.W., Pandyra, A., Boutros, P.C., et al. (2010) Dysregulation of the Mevalonate Pathway Promotes Transformation. Proceedings of the National Academy of Sciences of the United States of America, 107, 15051-15056. [Google Scholar] [CrossRef] [PubMed]
[24] Borgquist, S., Jögi, A., Pontén, F., Rydén, L., Brennan, D.J. and Jirström, K. (2008) Prognostic Impact of Tumour-Specific HMG-CoA Reductase Expression in Primary Breast Cancer. Breast Cancer Research, 10, R79. [Google Scholar] [CrossRef] [PubMed]
[25] Nielsen, S.F., Nordestgaard, B.G. and Bojesen, S.E. (2012) Statin Use and Reduced Cancer-Related Mortality. The New England Journal of Medicine, 368, 576-577. [Google Scholar] [CrossRef] 
[26] Garwood, E.R., Kumar, A.S., Baehner, F.L., et al. (2010) Fluvastatin Reduces Proliferation and Increases Apoptosis in Women with High Grade Breast Cancer. Breast Cancer Research and Treatment, 119, 137-144. [Google Scholar] [CrossRef] [PubMed]
[27] Bjarnadottir, O., Romero, Q., Bendahl, P.-O., et al. (2013) Targeting HMG-CoA Reductase with Statins in a Window-of-Opportunity Breast Cancer Trial. Breast Cancer Research and Treatment, 138, 499-508. [Google Scholar] [CrossRef] [PubMed]
[28] Bjarnadottir, O., Kimburg, S., Johansson, I., et al. (2015) Global Transcriptional Changes Following Statin Treatment in Breast Cancer. Clinical Cancer Research, 21, 3402-3411. [Google Scholar] [CrossRef] 
[29] Murtola, T.J., Visvanathan, K., Artama, M., Vainio, H. and Pukkala, E. (2014) Statin Use and Breast Cancer Survival: A Nationwide Cohort Study from Finland. PLoS ONE, 9, e110231. [Google Scholar] [CrossRef] [PubMed]
[30] Cardwell, C.R., Hicks, B.M. and Hughes, C.M.L. (2015) Statin Use after Diagnosis of Breast Cancer and Survival: A Population-Based Cohort Study. Epidemiology, 26, 68-78. [Google Scholar] [CrossRef] 
[31] Ahern, T.P., Pedersen, L., Tarp, M., et al. (2011) Statin Prescriptions and Breast Cancer Recurrence Risk: A Danish Nationwide Prospective Cohort Study. Journal of the National Cancer Institute, 103, 1461-1468. [Google Scholar] [CrossRef] [PubMed]

为你推荐